Skip to Content

New Drug Approvals Archive - May 2009

See also: New Indications and Dosage Forms for May 2009

May 2009

Cetraxal (ciprofloxacin otic) Solution

Date of Approval: May 1, 2009
Company: Salvat
Treatment for: Otitis Externa

Cetraxal (ciprofloxacin otic) is an antibiotic ear solution for the treatment of acute otitis externa.

Cycloset (bromocriptine mesylate) Tablets

Date of Approval: May 5, 2009
Company: VeroScience and S2 Therapeutics, Inc.
Treatment for: Diabetes Type 2

Cycloset (bromocriptine) is a first-in-class, central acting agent for the treatment of Type 2 Diabetes.

Fanapt (iloperidone) Tablets

Date of Approval: May 6, 2009
Company: Vanda Pharmaceuticals Inc.
Treatment for: Schizophrenia

Fanapt (iloperidone) is a 5HT2/D2 antagonist (atypical) antipsychotic for the treatment of schizophrenia.

Samsca (tolvaptan) Tablets

Date of Approval: May 19, 2009
Company: Otsuka Pharmaceutical Development & Commercialization, Inc.
Treatment for: Hyponatremia

Samsca (tolvaptan) is an oral selective vasopressin antagonist for the treatment of patients with clinically significant hypervolemic and euvolemic hyponatremia.

Adcirca (tadalafil) Tablets

Date of Approval: May 22, 2009
Company: United Therapeutics Corporation
Treatment for: Pulmonary Hypertension

Adcirca (tadalafil) is a once-daily phosphodiesterase type 5 (PDE5) inhibitor for the treatment of pulmonary arterial hypertension (PAH).

Besivance (besifloxacin) Ophthalmic Suspension

Date of Approval: May 28, 2009
Company: Bausch & Lomb
Treatment for: Bacterial Conjunctivitis

Besivance (besifloxacin ophthalmic suspension) is a topical quinolone antimicrobial for the treatment of bacterial conjunctivitis, commonly referred to as "pink eye."

New Drug Approvals Archive

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.